CA3057277C - Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative - Google Patents
Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative Download PDFInfo
- Publication number
- CA3057277C CA3057277C CA3057277A CA3057277A CA3057277C CA 3057277 C CA3057277 C CA 3057277C CA 3057277 A CA3057277 A CA 3057277A CA 3057277 A CA3057277 A CA 3057277A CA 3057277 C CA3057277 C CA 3057277C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- chemical formula
- adenosine
- present
- oral administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3159836A CA3159836C (en) | 2017-03-21 | 2018-03-21 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170035224A KR101805400B1 (ko) | 2017-03-21 | 2017-03-21 | 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물 |
| KR10-2017-0035224 | 2017-03-21 | ||
| PCT/KR2018/003274 WO2018174549A1 (ko) | 2017-03-21 | 2018-03-21 | 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3159836A Division CA3159836C (en) | 2017-03-21 | 2018-03-21 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3057277A1 CA3057277A1 (en) | 2018-09-27 |
| CA3057277C true CA3057277C (en) | 2022-07-26 |
Family
ID=60920336
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3057277A Active CA3057277C (en) | 2017-03-21 | 2018-03-21 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative |
| CA3159836A Active CA3159836C (en) | 2017-03-21 | 2018-03-21 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3159836A Active CA3159836C (en) | 2017-03-21 | 2018-03-21 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11185556B2 (https=) |
| EP (1) | EP3603647B1 (https=) |
| JP (1) | JP6821050B2 (https=) |
| KR (1) | KR101805400B1 (https=) |
| CN (1) | CN110381955A (https=) |
| AU (1) | AU2018238996B2 (https=) |
| CA (2) | CA3057277C (https=) |
| WO (1) | WO2018174549A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101805400B1 (ko) | 2017-03-21 | 2017-12-07 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물 |
| KR102007640B1 (ko) | 2017-11-29 | 2019-08-07 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 망막 질환 또는 시신경 질환 예방 및 치료용 약학적 조성물 |
| CN116350649A (zh) * | 2021-12-28 | 2023-06-30 | 未来制药有限公司 | 预防和/或治疗胆管炎或由其引起的肝疾病的药物组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009003750A (es) | 2006-10-06 | 2009-06-18 | Univ Pennsylvania | Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular. |
| WO2008108508A1 (en) * | 2007-03-07 | 2008-09-12 | Fm Therapeutics Co., Ltd. | Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient |
| WO2012125400A1 (en) * | 2011-03-14 | 2012-09-20 | Acorn Biomedical, Inc. | Compositions and methods using adenosine a3 receptor antagonists for the treatment of inflammatory eye diseases |
| KR101805400B1 (ko) * | 2017-03-21 | 2017-12-07 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물 |
| KR101820909B1 (ko) * | 2017-07-07 | 2018-01-23 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물 |
-
2017
- 2017-03-21 KR KR1020170035224A patent/KR101805400B1/ko active Active
-
2018
- 2018-03-21 CA CA3057277A patent/CA3057277C/en active Active
- 2018-03-21 CN CN201880015381.7A patent/CN110381955A/zh active Pending
- 2018-03-21 EP EP18771758.2A patent/EP3603647B1/en active Active
- 2018-03-21 JP JP2019547971A patent/JP6821050B2/ja active Active
- 2018-03-21 CA CA3159836A patent/CA3159836C/en active Active
- 2018-03-21 AU AU2018238996A patent/AU2018238996B2/en active Active
- 2018-03-21 US US16/492,938 patent/US11185556B2/en active Active
- 2018-03-21 WO PCT/KR2018/003274 patent/WO2018174549A1/ko not_active Ceased
-
2021
- 2021-08-26 US US17/458,231 patent/US12083140B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020511437A (ja) | 2020-04-16 |
| AU2018238996A1 (en) | 2019-10-24 |
| EP3603647B1 (en) | 2024-08-21 |
| WO2018174549A1 (ko) | 2018-09-27 |
| US20200016186A1 (en) | 2020-01-16 |
| AU2018238996B2 (en) | 2021-01-28 |
| US20210386771A1 (en) | 2021-12-16 |
| EP3603647A4 (en) | 2021-01-06 |
| JP6821050B2 (ja) | 2021-01-27 |
| CA3159836C (en) | 2026-02-10 |
| US12083140B2 (en) | 2024-09-10 |
| KR101805400B1 (ko) | 2017-12-07 |
| US11185556B2 (en) | 2021-11-30 |
| CA3159836A1 (en) | 2018-09-27 |
| CA3057277A1 (en) | 2018-09-27 |
| CN110381955A (zh) | 2019-10-25 |
| EP3603647A1 (en) | 2020-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2680179C (en) | Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient | |
| JP7175525B2 (ja) | アデノシン誘導体を含む非アルコール性脂肪肝炎、肝線維症及び肝硬変症の予防及び治療用薬学的組成物 | |
| ES2217279T3 (es) | Compuestos con propiedades antihipertensivas, cardioprotectoras, anti-isquemicas y antilipoliticas. | |
| US12083140B2 (en) | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | |
| KR101396092B1 (ko) | 아데노신 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 약학적 조성물 | |
| Hutchinson et al. | A1 adenosine receptor agonists: medicinal chemistry and therapeutic potential | |
| ES2333651T3 (es) | Agonistas del receptor de adenosina a3. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190919 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250321 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250321 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250321 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260225 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260225 |